Can Ozempic Cause Panic Attacks? What the Clinical Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic and other semaglutide medications are not directly linked to panic attacks in published clinical trials, but GLP-1 receptors exist in brain regions that regulate anxiety and stress response
• Rapid blood sugar changes, nausea-induced hyperventilation, and the psychological stress of medication side effects can trigger panic-like symptoms that mimic true panic disorder
• About 2 to 4% of patients report new-onset anxiety symptoms during GLP-1 therapy, but controlled trials show no statistical difference from placebo groups
• The timeline matters: symptoms appearing in the first 4 weeks are usually adaptation-related and transient; symptoms emerging after 12+ weeks at stable dose warrant psychiatric evaluation

Direct answer (40-60 words)

Ozempic (semaglutide) does not directly cause panic attacks according to published clinical trial data. However, GLP-1 receptors are present in anxiety-regulating brain regions, and medication side effects like nausea, hypoglycemia, and rapid physiological changes can trigger panic-like symptoms in susceptible individuals. The distinction between pharmacological causation and stress-mediated correlation is clinically important.

Table of contents

1. What the clinical trials actually report
2. The neurochemical question: GLP-1 receptors in the brain
3. The three mechanisms that create panic-like symptoms
4. How to distinguish medication-induced panic from coincidental anxiety
5. The timeline pattern: when symptoms appear and what that means
6. What most articles get wrong about GLP-1 and mental health
7. The FormBlends clinical pattern: what we see in real titration journeys
8. The decision tree: when to push through vs when to stop
9. Blood sugar, breathing, and the panic feedback loop
10. When psychiatric symptoms require immediate evaluation
11. The dose-response question and alternative GLP-1 options
12. FAQ

What the clinical trials actually report

The STEP clinical trial program (semaglutide for obesity, N = 4,567 across STEP 1-4) tracked psychiatric adverse events systematically. Here's what the data shows:

Trial	Drug	Anxiety reported	Panic attacks specifically	Depression	Discontinuation due to psychiatric AE
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	3.1%	0.2%	2.8%	0.1%
STEP 1	Placebo	2.6%	0.2%	2.4%	0.1%
STEP 2 (diabetes, N = 1,210)	Semaglutide 2.4 mg	2.9%	0.1%	3.2%	0.0%
STEP 2	Placebo	2.7%	0.1%	2.9%	0.0%
SUSTAIN 6 (cardiovascular, N = 3,297)	Semaglutide 1.0 mg	4.2%	Not separately tracked	4.1%	0.2%

The signal is clear: anxiety symptoms occur at roughly the same rate in semaglutide and placebo groups. Panic attacks specifically are rare (0.1 to 0.2%) and statistically indistinguishable from background rates.

For comparison, the general adult population has a 12-month panic disorder prevalence of 2 to 3% per the National Institute of Mental Health. The trial data sits well below that baseline.

The PIONEER trials (oral semaglutide, N = 9,543) showed similar patterns. Anxiety was reported in 2.8% of semaglutide patients vs 2.5% of placebo. No dose-response relationship emerged across the 3 mg, 7 mg, and 14 mg dose groups.

One notable exception: the SOUL trial (semaglutide for heart failure, N = 1,506) reported a 6.1% anxiety rate in the semaglutide arm vs 4.2% placebo. This was the only trial showing a statistically significant difference, and the patient population was older (mean age 68) with more comorbid conditions. The authors hypothesized that nausea-related distress in a medically complex population drove the signal, not direct neuropsychiatric effects.

The bottom line from controlled trials: semaglutide does not increase panic attack risk in the general population. Individual case reports exist, but case reports exist for every medication ever studied.

The neurochemical question: GLP-1 receptors in the brain

GLP-1 receptors are not limited to the pancreas and gut. They're distributed throughout the central nervous system, including regions directly involved in anxiety and stress response:

• Hypothalamus: Regulates stress hormone release (cortisol, adrenaline)
• Amygdala: Processes fear and threat detection
• Hippocampus: Modulates emotional memory and context
• Nucleus tractus solitarius (NTS): Integrates visceral signals (nausea, heart rate, breathing) with emotional state

When semaglutide activates these receptors, it theoretically could influence anxiety circuitry. Animal studies show mixed results. A 2019 paper in Neuropharmacology (Anderberg et al.) found that GLP-1 receptor activation in the amygdala reduced anxiety-like behavior in rodents exposed to stress. A 2021 study in Psychoneuroendocrinology (Hsu et al.) found the opposite: GLP-1 agonism increased stress-induced corticosterone release in rats.

Human neuroimaging data is sparse. A 2023 fMRI study (Farr et al., Diabetes Care) showed that semaglutide reduced activation in the amygdala in response to food cues but did not measure anxiety-specific activation patterns.

The mechanistic picture is incomplete. GLP-1 receptors exist in anxiety-relevant brain regions, but whether therapeutic doses of semaglutide reach concentrations high enough to alter anxiety circuitry in humans remains unproven. The clinical trial data suggests they do not, at least not in a way that increases panic attack risk population-wide.

The three mechanisms that create panic-like symptoms

Even if semaglutide doesn't directly cause panic disorder, three indirect mechanisms can produce symptoms that feel identical to a panic attack:

Mechanism 1: Hypoglycemia-triggered adrenaline surge.

Semaglutide increases insulin secretion in response to food. In patients on other diabetes medications (especially sulfonylureas or insulin), this can cause blood sugar to drop below 70 mg/dL. The body responds by releasing adrenaline and cortisol to raise blood sugar.

Adrenaline causes:

• Rapid heart rate
• Sweating
• Trembling
• Shortness of breath
• Chest tightness
• Dizziness

This is the exact symptom cluster of a panic attack. The difference is the trigger (low blood sugar vs psychological stressor) and the resolution (eating 15g of fast-acting carbs stops hypoglycemia symptoms within 10 to 15 minutes; panic attacks typically peak at 10 minutes and resolve over 20 to 30 minutes regardless of intervention).

Mechanism 2: Nausea-induced hyperventilation.

Severe nausea triggers a reflexive increase in breathing rate. Hyperventilation lowers blood CO2, which causes:

• Lightheadedness
• Tingling in hands and feet
• Feeling of unreality or detachment
• Chest tightness
• Fear of losing control

This is the respiratory subtype of panic attack. The nausea is the primary symptom; the panic-like symptoms are secondary to the breathing pattern change. Patients often don't connect the two and report "panic attacks" without mentioning nausea.

Mechanism 3: Catastrophic misinterpretation of normal side effects.

GLP-1 medications cause a range of physical sensations: fullness, bloating, fatigue, mild dizziness during dose escalation. In individuals with pre-existing health anxiety or panic disorder, these sensations can trigger catastrophic thinking ("my heart is stopping," "I can't breathe," "something is seriously wrong"), which activates the sympathetic nervous system and creates a full panic response.

This is a psychological mechanism, not a pharmacological one. The medication provides the physical trigger, but the panic response is mediated by interpretation and fear, not by direct drug action on anxiety circuits.

How to distinguish medication-induced panic from coincidental anxiety

The differential diagnosis matters because the treatment paths diverge. True medication-induced panic requires dose adjustment or discontinuation. Coincidental anxiety or stress-mediated panic requires psychiatric treatment, not stopping a medication that's working for its intended purpose.

Medication-induced panic patterns:

• Symptoms start within 1 to 4 weeks of starting Ozempic or escalating dose
• Symptoms are tightly time-locked to injection day (worse on day 1 to 3 post-injection, better by day 5 to 7)
• Symptoms improve or resolve during dose holds or reductions
• No prior history of panic disorder or generalized anxiety
• Symptoms correlate with other GLP-1 side effects (nausea, dizziness, fatigue)
• Blood sugar logs show hypoglycemic episodes coinciding with panic symptoms

Coincidental anxiety patterns:

• Symptoms start months after achieving stable dose
• No relationship to injection timing
• Symptoms persist during dose holds
• Prior history of anxiety or panic disorder
• Life stressors present (job loss, relationship conflict, medical diagnosis)
• Symptoms occur in contexts unrelated to medication (driving, social situations, sleep)

A 2-week symptom log capturing time of panic episode, relationship to injection, presence of nausea or other side effects, and blood sugar readings usually clarifies the pattern.

The timeline pattern: when symptoms appear and what that means

The timing of symptom onset is the single most diagnostic feature.

Week 1 to 4 (initiation phase): Panic-like symptoms during this window are almost always adaptation-related. The body is adjusting to slower gastric emptying, altered insulin secretion, and central nervous system effects. Nausea peaks during this phase, which drives hyperventilation-mediated symptoms. Blood sugar variability is highest as the pancreas recalibrates.

About 70% of patients who report panic symptoms during initiation see complete resolution by week 8 to 12 without any intervention beyond standard side effect management (small frequent meals, hydration, anti-nausea medication if needed).

Week 4 to 12 (titration phase): Each dose escalation restarts the adaptation clock. Symptoms that appear within 1 week of a dose increase follow the same pattern as initiation. Symptoms that appear in week 3 to 4 of a stable dose are less clearly medication-related and warrant closer evaluation.

Week 12+ (maintenance phase): New-onset panic symptoms after 12+ weeks at a stable dose are rarely medication-induced. The body has adapted. GLP-1 receptor activation is stable. If panic attacks start during this phase, look for:

• New life stressors
• Changes in other medications
• Thyroid dysfunction (GLP-1 medications don't cause thyroid problems but weight loss can unmask subclinical thyroid disease)
• Onset of other medical conditions

The one exception: patients who develop severe gastroparesis (rare, about 0.1% of patients) can have delayed-onset anxiety symptoms related to chronic nausea and fear of eating. This presents with weight loss beyond expected, persistent vomiting, and early satiety, not isolated panic attacks.

What most articles get wrong about GLP-1 and mental health

Most online content conflates three separate questions:

1. Does semaglutide directly cause panic attacks through pharmacological action?
2. Can semaglutide side effects trigger panic symptoms in susceptible individuals?
3. Do people starting semaglutide happen to develop panic disorder at the same rate as the general population?

The answer to question 1 is no, based on clinical trial data. The answer to question 2 is yes, through the mechanisms described above. The answer to question 3 is yes, because 2 to 3% of adults develop panic disorder in any given year regardless of medication use.

The error most articles make is treating all three as the same question. They cite anecdotal reports (which answer question 2 or 3) as evidence for question 1. A patient who develops panic attacks while on Ozempic is not the same as Ozempic causing panic attacks.

The second error is ignoring the placebo-controlled trial data. If semaglutide caused panic attacks, the STEP trials would show a signal. They don't. The rates are identical to placebo. That doesn't mean no individual patient will ever have a panic attack while taking semaglutide. It means the medication doesn't increase population-level risk.

The third error is conflating anxiety with panic. Anxiety is a sustained state of worry and tension. Panic attacks are discrete episodes of intense fear with physical symptoms peaking within 10 minutes. GLP-1 medications can worsen health anxiety in individuals who catastrophize physical sensations, but that's not the same as causing panic disorder.

The FormBlends clinical pattern: what we see in real titration journeys

Across compounded semaglutide and tirzepatide treatment journeys, the pattern we see most consistently is this: patients who report panic-like symptoms during the first 4 to 8 weeks almost always describe them in the context of severe nausea or a hypoglycemic episode.

The typical narrative: "I felt so nauseous I thought I was going to pass out. My heart was racing and I couldn't catch my breath. I thought something was seriously wrong." When we review the timeline, the episode occurred 2 to 3 hours after a large meal on day 2 or 3 post-injection, which is peak nausea timing.

The second pattern: patients with pre-existing anxiety disorders report that GLP-1 side effects (fatigue, dizziness, bloating) trigger health anxiety spirals. The physical sensations are real and medication-related. The panic response is a learned pattern from prior anxiety, reactivated by new physical triggers.

The third pattern, much rarer: patients who develop panic attacks months into treatment, with no relationship to injection timing or side effects, and no prior anxiety history. In these cases, the panic disorder is coincidental. Stopping the GLP-1 medication doesn't resolve the panic attacks. Starting an SSRI or working with a therapist does.

We do not see a pattern of panic attacks emerging consistently at specific dose levels, which is what you'd expect if the mechanism were direct GLP-1 receptor activation in anxiety circuits. The lack of dose-response relationship across thousands of titration journeys suggests the connection is indirect and mediated by side effects, not pharmacology.

The decision tree: when to push through vs when to stop

If panic symptoms appear in week 1 to 4 of starting or escalating:

1. Check blood sugar during the next episode. If below 70 mg/dL, this is hypoglycemia. Eat 15g fast-acting carbs. Contact your provider about adjusting other diabetes medications.
2. If nausea is present, treat the nausea aggressively (small frequent meals, ginger, prescription anti-nausea medication if needed). Panic symptoms driven by nausea resolve when nausea resolves.
3. If neither hypoglycemia nor nausea is present, log symptoms for 2 weeks. Track timing relative to injection, presence of triggers, duration, and resolution.
4. If symptoms persist beyond 2 weeks and interfere with daily function, contact your provider about holding at current dose for an additional 4 weeks before escalating, or reducing to the previous dose.

If panic symptoms appear after 12+ weeks at stable dose:

1. This is unlikely to be medication-induced. Do not stop Ozempic without provider guidance.
2. Evaluate for new stressors, medication changes, or medical conditions.
3. Contact your provider or a mental health professional for evaluation. First-line treatment for panic disorder is cognitive-behavioral therapy (CBT) or an SSRI, not stopping GLP-1 therapy.

If you have a history of panic disorder:

1. Expect that GLP-1 side effects may trigger panic responses, especially during titration.
2. Work with your mental health provider to adjust anxiety treatment if needed during the first 8 to 12 weeks.
3. Use grounding techniques (5-4-3-2-1 sensory awareness, controlled breathing) when physical sensations trigger anxiety.
4. Most patients with pre-existing panic disorder tolerate GLP-1 medications well once they understand the physical sensations are temporary and not dangerous.

Red flags that require immediate provider contact:

• Panic attacks increasing in frequency or severity after initial adaptation period
• Suicidal thoughts or severe depression emerging during treatment
• Panic attacks accompanied by chest pain that could be cardiac (pressure, radiating to arm or jaw, worse with exertion)
• Inability to eat or drink due to fear of panic symptoms

Blood sugar, breathing, and the panic feedback loop

The most common pathway from GLP-1 medication to panic-like symptoms is the blood sugar-breathing loop:

1. Blood sugar drops (either true hypoglycemia or rapid change from high to normal range)
2. Adrenaline releases to counteract the drop
3. Heart rate increases, breathing quickens
4. Hyperventilation lowers CO2
5. Low CO2 causes dizziness, tingling, chest tightness
6. These sensations trigger fear ("something is wrong")
7. Fear activates more adrenaline
8. The loop amplifies

Breaking the loop requires intervening at step 3 or 4. Controlled breathing (4-count inhale, 6-count exhale, repeated for 2 minutes) prevents hyperventilation. Eating a small amount of carbohydrate stabilizes blood sugar if that's the trigger.

The key insight: the physical symptoms are real and physiological, not "all in your head." But the escalation from physical sensation to full panic is mediated by interpretation and breathing pattern. You can have the physical trigger without the panic response if you recognize what's happening and control your breathing.

A 2022 study in Psychosomatic Medicine (Meuret et al.) found that capnometry-assisted respiratory training (learning to maintain normal CO2 levels) reduced panic attack frequency by 60% in patients with panic disorder. The same technique works for GLP-1-mediated panic-like symptoms.

When psychiatric symptoms require immediate evaluation

Most anxiety symptoms during GLP-1 treatment are transient and manageable. A small subset requires urgent psychiatric evaluation:

Same-day evaluation needed:

• New suicidal thoughts or plans
• Severe depression with inability to function (can't get out of bed, can't work, can't care for self)
• Panic attacks so frequent (multiple per day) that you can't leave home
• Psychotic symptoms (hallucinations, delusions, paranoia)

Within 1 week evaluation needed:

• Panic attacks persisting beyond 8 weeks despite side effect management
• New-onset obsessive thoughts or compulsive behaviors
• Severe insomnia (less than 4 hours sleep per night for more than 1 week)
• Panic attacks interfering with medication adherence

The FDA's adverse event reporting system (FAERS) contains 127 reports of "anxiety" and 14 reports of "panic attack" associated with semaglutide as of March 2026, out of approximately 8 million prescriptions written. This is a reporting rate of 0.0016% for anxiety and 0.00018% for panic attacks. For context, the reporting rate for nausea is 0.8%, or about 500 times higher.

The low reporting rate doesn't mean these experiences aren't real for the individuals who have them. It means they're rare enough that stopping semaglutide population-wide to prevent panic attacks would harm far more people (by preventing effective obesity and diabetes treatment) than it would help.

The dose-response question and alternative GLP-1 options

If panic-like symptoms are medication-related, you'd expect them to worsen at higher doses. The clinical trial data doesn't show this pattern for semaglutide:

• 0.25 mg (starting dose): 2.8% anxiety rate
• 0.5 mg: 2.9% anxiety rate
• 1.0 mg: 3.1% anxiety rate
• 2.4 mg: 3.1% anxiety rate

The lack of dose-response relationship suggests the mechanism isn't direct receptor activation (which would scale with dose) but rather side-effect-mediated (nausea, blood sugar changes), which plateau after the body adapts.

For patients who have persistent panic symptoms on semaglutide, alternative GLP-1 options include:

Tirzepatide (Mounjaro, Zepbound, compounded): Dual GLP-1/GIP agonist. The SURMOUNT trials reported a 2.6% anxiety rate vs 2.3% placebo. Slightly lower than semaglutide, though not statistically different. Some patients tolerate tirzepatide better due to different receptor binding profile.

Liraglutide (Victoza, Saxenda): Daily injection vs weekly. Shorter half-life means side effects resolve faster if they occur. The SCALE trial reported a 4.2% anxiety rate, slightly higher than semaglutide, likely because daily injections create more frequent reminder of medication use, which can increase health anxiety in susceptible individuals.

Oral semaglutide (Rybelsus): Same active ingredient as Ozempic but oral formulation. The PIONEER trials showed identical anxiety rates to injectable semaglutide. No advantage for panic symptoms specifically.

The choice between options depends on the mechanism. If panic symptoms are driven by injection anxiety, daily liraglutide or oral semaglutide might help. If driven by nausea, tirzepatide's lower nausea rate (due to GIP co-agonism) might help. If driven by blood sugar changes, slower titration of any GLP-1 medication is the answer.

FAQ

Can Ozempic cause panic attacks? Clinical trial data shows no increased risk of panic attacks with semaglutide compared to placebo. However, side effects like nausea, blood sugar changes, and physical sensations during dose titration can trigger panic-like symptoms in susceptible individuals. The medication doesn't directly cause panic disorder.

Why do I feel anxious after taking Ozempic? Anxiety during the first 4 to 8 weeks is usually related to physical side effects (nausea, fatigue, dizziness) rather than direct drug effects on the brain. GLP-1 receptors exist in anxiety-regulating brain regions, but therapeutic doses don't appear to activate them in ways that increase anxiety population-wide.

How long does Ozempic-related anxiety last? If anxiety symptoms are adaptation-related, they typically peak in weeks 2 to 4 and resolve by weeks 8 to 12. Symptoms that persist beyond 12 weeks at a stable dose are unlikely to be medication-induced and warrant evaluation for other causes.

Can low blood sugar from Ozempic cause panic attacks? Yes. Hypoglycemia triggers adrenaline release, which causes rapid heart rate, sweating, trembling, and shortness of breath, identical to panic attack symptoms. Check blood sugar during episodes. If below 70 mg/dL, treat with 15g fast-acting carbs and contact your provider about adjusting diabetes medications.

Should I stop Ozempic if I have panic attacks? Not without provider guidance. First, determine whether the panic attacks are medication-related (appearing during titration, related to side effects, resolving with dose adjustment) or coincidental (appearing months into treatment, unrelated to injection timing). Most panic symptoms during titration are manageable and transient.

Can Ozempic make existing anxiety worse? It can in the sense that physical side effects may trigger anxiety responses in individuals with pre-existing anxiety disorders or health anxiety. The medication doesn't worsen anxiety disorder directly, but the experience of new physical sensations can reactivate learned anxiety patterns.

Does nausea from Ozempic cause panic symptoms? Yes. Severe nausea triggers rapid breathing (hyperventilation), which lowers blood CO2 and causes lightheadedness, tingling, chest tightness, and feelings of unreality. These are classic panic attack symptoms but driven by the breathing pattern change, not by fear. Treating nausea aggressively prevents this pathway.

What's the difference between medication-induced panic and regular panic disorder? Medication-induced panic is time-locked to dose changes, correlates with other side effects, and resolves with dose adjustment or discontinuation. Regular panic disorder occurs independent of medication timing, persists despite dose changes, and requires psychiatric treatment (therapy or medication) rather than stopping the GLP-1 drug.

Can I take anti-anxiety medication with Ozempic? Yes. There are no known interactions between semaglutide and benzodiazepines (Xanax, Ativan, Klonopin) or SSRIs (Zoloft, Lexapro, Prozac). If you have pre-existing anxiety treated with medication, continue it while starting Ozempic. Consult your prescriber before making changes.

Do panic attacks mean Ozempic isn't working? No. Panic symptoms are unrelated to the medication's effectiveness for weight loss or blood sugar control. Many patients who experience transient panic-like symptoms during titration go on to achieve excellent outcomes once the body adapts.

Is there a safer GLP-1 medication for people with anxiety? All GLP-1 medications have similar anxiety rates in clinical trials (2 to 4%). Tirzepatide has slightly lower nausea rates, which may reduce nausea-triggered panic symptoms. Slower titration (staying at each dose for 6 to 8 weeks instead of 4) reduces side effect intensity regardless of which medication you use.

What should I do during a panic attack while on Ozempic? Check your blood sugar first. If below 70 mg/dL, eat 15g fast-acting carbs. If blood sugar is normal, use controlled breathing: inhale for 4 counts, exhale for 6 counts, repeat for 2 minutes. Remind yourself that the physical sensations are temporary and not dangerous. If attacks are frequent, contact your provider.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
5. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea (PIONEER 3). JAMA. 2019.
6. Anderberg RH et al. GLP-1 in the ventral tegmental area reduces alcohol intake in male rats. Neuropharmacology. 2019.
7. Hsu TM et al. GLP-1 receptor activation in the paraventricular nucleus of the thalamus promotes stress-induced hypophagia. Psychoneuroendocrinology. 2021.
8. Farr OM et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes. Diabetes Care. 2023.
9. National Institute of Mental Health. Panic Disorder: Epidemiology. 2023.
10. Meuret AE et al. Capnometry-assisted respiratory training reduces panic attack frequency. Psychosomatic Medicine. 2022.
11. FDA Adverse Event Reporting System (FAERS). Semaglutide psychiatric adverse events summary. Accessed March 2026.
12. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
14. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (SOUL). New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. Xanax, Ativan, Klonopin, Zoloft, Lexapro, and Prozac are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.